Recent advancements in the treatment of Tenosynovial Giant Cell Tumor (TGCT) have introduced targeted therapies that offer new hope for patients with symptomatic or unresectable disease. This session will provide an in-depth overview of available therapeutic options, including newly approved agents, their clinical indications, mechanisms of action, and safety profiles. We will also discuss key considerations for patient selection, monitoring, and managing adverse effects to optimize outcomes.
